NACI released recommendations surrounding the optimal interval for booster doses in vaccinated individuals who have recently become infected with COVID-19.
Individuals 5 years-of-age and older, infected with COVID-19 prior to their completion -or initiation of primary vaccine series are recommended to receive the next dose of vaccine 8 weeks after symptom onset or positive test.
Individuals 18 years of age and older, infected with COVID-19 after their primary series but before their booster dose, are recommended to receive their booster dose 3 months after symptom onset or positive test.
Individuals 12-17 year-of-age, infected with COVID-19 after their primary series but before their booster dose, are recommended to receive their booster dose 3 months after symptom onset or positive test, provided it's been at least 6 months after completing the primary series.
Individuals 5+ years-of-age who are not considered moderately to severely immunocompromised and with no previous history of multisystem inflammatory syndrome (MIS-C) in children can receive their first or second vaccine 8 weeks after symptom onset or positive test.
Individuals 5+ years-of-age who are moderately to severely immunocompromised and with no previous history of MIS-C can receive their first or second vaccine dose 4 to 8 weeks after symptoms onset or positive test.
Individuals 5+ years-of-age with a previous history of MIS-C (regardless of immunocompromised status) can receive their first or second vaccine dose when clinical recovery has been achieved or greater than 90 days since the onset of MIS-C, whichever is longer.
The recommended waiting times between the COVID-19 infection and vaccination are intended to minimize the risk of transmission of COVID-19 at an immunization clinic, enable monitoring for COVID-19 vaccine adverse events and increase immune response to vaccine. However, with informed consent individuals may opt to receive their first, second or a booster dose after symptoms of COVID-19 have resolved and they are no longer infectious.